Tumor Genomic Subtype Might Influence Level of ctDNA Shedding in NSCLC
Investigators retrospectively analyzed circulating tumor DNA (ctDNA)-based and tissue-based genomic data from 144 patients with non-small cell lung cancer (NSCLC).
Investigators retrospectively analyzed circulating tumor DNA (ctDNA)-based and tissue-based genomic data from 144 patients with non-small cell lung cancer (NSCLC).
Investigators analyzed the effect of EGFR inhibition on VEGF and HIF-1α in non-small cell lung cancer models.
Investigators assessed the impact of immune checkpoint inhibition in patients with non–small lung cancer and MET-amplified or MET exon 14-mutant tumors.
The study results can inform decision making during the COVID-19 and future pandemics.
About one-third of patients refractory to alectinib responded.
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Extracellular vesicles carrying PD-L1 as cargo may function as a predictive biomarker for immunotherapy response in NSCLC.
At 2 years, twice as many patients with stage II to IIIA disease in the osimertinib group were alive and disease-free as in the placebo group.
This analysis compared the efficacy outcomes of subgroups of patients with NSCLC treated with alectinib vs crizotinib according to ALK tumor status.
Neoadjuvant treatment with chemotherapy plus nivolumab resulted in a greater frequency of NSCLC downstaging compared with chemotherapy or ICI treatment alone.